WuXi AppTec Co., Ltd. (SHA:603259)
China · Delayed Price · Currency is CNY | Market Cap | 472.95B +44.1% |
| Revenue (ttm) | 51.52B +28.3% |
| Net Income | 21.77B +58.8% |
| EPS | 7.37 +53.6% |
| Shares Out | 2.94B |
| PE Ratio | 22.92 |
| Forward PE | 18.09 |
| Dividend | 1.93 (1.22%) |
| Ex-Dividend Date | Sep 4, 2026 |
| Volume | 60,449,666 |
| Open | 162.00 |
| Previous Close | 162.00 |
| Day's Range | 151.62 - 162.50 |
| 52-Week Range | 87.09 - 173.60 |
| Beta | 0.53 |
| Analysts | Strong Buy |
| Price Target | 190.75 (+20.88%) |
| Earnings Date | Oct 27, 2026 |
About WuXi AppTec
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People’s Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manufacturing organization (CDRMO) services for new drug development from discovery to commercial covering various categories for various synthetic molecula... [Read more]
Financial Performance
In 2025, WuXi AppTec's revenue was 43.42 billion, an increase of 21.40% compared to the previous year's 35.77 billion. Earnings were 19.15 billion, an increase of 102.65%.
Financial StatementsAnalyst Summary
According to 21 analysts, the average rating for 603259 stock is "Strong Buy." The 12-month stock price target is ¥190.75, which is an increase of 20.88% from the latest price.
News
WuXi AppTec Earns EcoVadis Gold Medal for Third Consecutive Year, Ranking Among Global Top 5% for Sustainability
SHANGHAI, Oct. 7, 2026 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has received a Gold medal from EcoVadis for ...
WuXi AppTec Continues to Reward Shareholders, Further Increasing Interim Dividend to RMB 1.51 Billion
SHANGHAI, Aug. 30, 2026 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), ...
Judge blocks US decision to add WuXi to list of firms tied to Chinese military
A U.S. judge on Friday barred the Defense Department from including Chinese biotechnology company WuXi AppTec Co on a list of companies believed to support Beijing's military, saying the government ...
WuXi AppTec Quarterly report: Q2 2026
WuXi AppTec has published its Q2 2026 quarterly earnings report on August 3, 2026.
WuXi AppTec files complaint against U.S. DoD for linking it to Chinese military
WuXi AppTec said on Thursday that it has filed a complaint at the United States District Court for the District of Columbia against the Department of Defense for including the company in ...
WuXi AppTec Recognized as a Top-Performing Company on 2026 Dow Jones Best-in-Class World Index
SHANGHAI, May 17, 2026 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has been selected for the 2026 Dow Jones Bes...
WuXi AppTec Delivers Strong Revenue and Profit Growth in Q1 2026
Total Revenue Reached RMB 12.44 Billion; Revenue from Continuing Operations Up 39.4% YoY Adjusted Non-IFRS Net Profit Up 71.7% YoY to RMB 4.60 Billion Backlog for Continuing Operations Up 23.6% YoY to...
WuXi AppTec Slides: Q1 2026
WuXi AppTec has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 27, 2026.
WuXi AppTec Quarterly report: Q1 2026
WuXi AppTec has published its Q1 2026 quarterly earnings report on April 27, 2026.
WuXi AppTec Earnings Call Transcript: H2 2025
Record 2025 results with revenue up 21.4% and adjusted net profit up 41.3% year-over-year. 2026 guidance targets 18–22% revenue growth, robust cash flow, and continued global expansion, supported by a strong backlog and resilient business model.
WuXi AppTec Annual report: H2 2025
WuXi AppTec has published its H2 2025 annual report on March 23, 2026.
WuXi AppTec Slides: H2 2025
WuXi AppTec has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 23, 2026.
WuXi AppTec Beat Full-Year Guidance and Achieved Record Performance in 2025
2025 Total Revenue Reached RMB 45.46 Billion; Revenue from Continuing Operations Up 21.4% YoY Adjusted Non-IFRS Net Profit Up 41.3% YoY to RMB 14.96 Billion Backlog for Continuing Operations Up 28.8% ...
WuXi AppTec Receives Double "A" Rating from CDP for Climate Change and Water Security Leadership
SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced that it has been recognized...
WuXi AppTec Transcript: 44th Annual J.P. Morgan Healthcare Conference
Record 2025 revenue and profit were driven by strong GLP-1 demand, robust pipeline growth, and expanding global capacity. The company continues to invest in peptides, oligonucleotides, and small molecules, with further capacity increases planned for 2026. ESG leadership, operational excellence, and digital innovation underpin sustained growth.
WuXi AppTec Slides: 44th Annual J.P. Morgan Healthcare Conference
WuXi AppTec has posted slides in relation to its latest quarterly earnings report, which was published on January 14, 2026.
WuXi AppTec Receives Frost & Sullivan's 2025 Global Company of the Year Award in the CRDMO Industry
SHANGHAI, MIDDLETOWN, Del. and MUNICH , Nov. 19, 2025 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has been reco...
WuXi AppTec Looks to Extend CRDMO Platform to Saudi Arabia as It Signs Strategic MoUs with NEOM and Ministry of Health
SHANGHAI , Oct. 28, 2025 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced it has signed two strategi...
WuXi AppTec Earnings Call Transcript: Q3 2025
Record revenue and profit growth in the first three quarters, driven by strong performance in small molecule and TIDES businesses, with robust backlog and improved margins. Raised full-year guidance, accelerated global expansion, and announced divestiture of China-based clinical research services.
WuXi AppTec Quarterly report: Q3 2025
WuXi AppTec has published its Q3 2025 quarterly earnings report on October 26, 2025.
WuXi AppTec Slides: Q3 2025
WuXi AppTec has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 26, 2025.
WuXi AppTec Achieves Strong Double-Digit Growth in Revenue and Profit for Q1-Q3 2025 Backlog for Continuing Operations Up 41.2% YoY Further Raises 2025 Full-year Guidance
SHANGHAI, Oct. 26, 2025 /PRNewswire/ -- WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pha...
WuXi AppTec Implements Its First Interim Dividend Plan, Distributing RMB1.03 Billion in Cash Dividends
SHANGHAI, Sept. 21, 2025 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies ...
WuXi AppTec Awarded Gold Medal by EcoVadis Sustainability Rating for Second Consecutive Year
SHANGHAI , Sept. 8, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science indu...
WuXi AppTec Completes Second RMB1.0 Billion A-Share Repurchase Program in 2025, All Repurchased Shares to Be Cancelled
SHANGHAI , Aug. 27, 2025 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock codes: 603259.SH/2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies ...